U.S. development Phase success rates for oncology and non oncology drugs 2006-2015

This statistic shows the probability of success for new oncology and non-oncology drugs in the U.S. through the various stages of development, from January 1, 2006 to December 31, 2015. It was found that while the probability that a new non-oncology drug makes it from Phase I to approval was 11.9 percent, it was only 5.1 percent for oncology drugs.

Probability of success for oncology vs non-oncology drugs in the U.S. in the different development phases from 2006 to 2015

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

May 2016


United States

Survey time period

January 1, 2006 to December 31, 2015

Supplementary notes

* NDA - New Drug Application / BLA - Biologic License Application.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Clinical trials"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.